T. Rowe Price Investment Management, Inc. Catalent, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$42.56 - $59.82 $303 Million - $425 Million	-7,110,776 Reduced 63.44%	4,098,598 $231 Million
Q4 2023 Feb 14, 2024	SELL	$32.18 - $46.57 $72 Million - $104 Million	-2,237,000 Reduced 16.64%	11,209,374 $504 Million
Q3 2023 Nov 14, 2023	BUY	$44.2 - $50.2 $553,693 - $628,855	12,527 Added 0.09%	13,446,374 $612 Million
Q2 2023 Aug 14, 2023	BUY	$31.86 - $67.26 $44.9 Million - $94.8 Million	1,410,179 Added 11.73%	13,433,847 $582 Million
Q1 2023 May 15, 2023	SELL	$45.44 - $74.26 $207 Million - $338 Million	-4,555,278 Reduced 27.48%	12,023,668 $790 Million
Q4 2022 Feb 14, 2023	SELL	$41.39 - $81.0 $76.2 Million - $149 Million	-1,841,410 Reduced 10.0%	16,578,946 $746 Million
Q3 2022 Nov 14, 2022	BUY	$72.36 - $113.1 $1.33 Billion - $2.08 Billion	18,420,356 New	18,420,356 $1.33 Billion

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.